$CANN
TREES Corp (Colorado)

2021 Q1 Form 10-Q Financial Statement

#000155837021007388 Filed on May 17, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $1.648M $1.664M
YoY Change -0.97% 109.35%
Cost Of Revenue $555.2K $1.424M
YoY Change -61.01% 147.71%
Gross Profit $1.093M $240.2K
YoY Change 354.93% 9.15%
Gross Profit Margin 66.31% 14.43%
Selling, General & Admin $598.7K $1.040M
YoY Change -42.43% -66.3%
% of Gross Profit 54.79% 432.93%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $121.9K $34.09K
YoY Change 257.73% -20.62%
% of Gross Profit 11.16% 14.19%
Operating Expenses $598.7K $1.040M
YoY Change -42.43% -66.51%
Operating Profit -$974.0K -$2.001M
YoY Change -51.33% -30.64%
Interest Expense $103.1K $171.0K
YoY Change -39.75% -113.34%
% of Operating Profit
Other Income/Expense, Net -$1.372M $139.9K
YoY Change -1080.22%
Pretax Income -$2.346M -$1.861M
YoY Change 26.02% -55.34%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.359M -$2.000M
YoY Change 17.95% -55.69%
Net Earnings / Revenue -143.15% -120.18%
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share -$0.04 -$50.74K
COMMON SHARES
Basic Shares Outstanding 61.56M
Diluted Shares Outstanding 61.56M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $840.1K $594.5K
YoY Change 41.32% -89.36%
Cash & Equivalents $840.1K $775.3K
Short-Term Investments
Other Short-Term Assets $382.3K $1.073M
YoY Change -64.36% 100.63%
Inventory $419.8K
Prepaid Expenses $376.9K
Receivables $299.9K $65.93K
Other Receivables $260.0K $470.8K
Total Short-Term Assets $2.202M $2.204M
YoY Change -0.09% -69.19%
LONG-TERM ASSETS
Property, Plant & Equipment $666.3K $204.6K
YoY Change 225.63% -88.25%
Goodwill $2.484M
YoY Change
Intangibles $912.5K
YoY Change
Long-Term Investments $0.00 $250.0K
YoY Change -100.0% 0.0%
Other Assets
YoY Change
Total Long-Term Assets $5.890M $454.6K
YoY Change 1195.46% -78.9%
TOTAL ASSETS
Total Short-Term Assets $2.202M $2.204M
Total Long-Term Assets $5.890M $454.6K
Total Assets $8.092M $2.659M
YoY Change 204.35% -71.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $733.1K $1.281M
YoY Change -42.76% 390.18%
Accrued Expenses $540.6K $153.2K
YoY Change 252.79% -78.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $99.67K
YoY Change -100.0%
Long-Term Debt Due $2.640M
YoY Change -59.03%
Total Short-Term Liabilities $1.640M $8.354M
YoY Change -80.37% 7.91%
LONG-TERM LIABILITIES
Long-Term Debt $3.570M $0.00
YoY Change
Other Long-Term Liabilities $1.497M
YoY Change
Total Long-Term Liabilities $3.570M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.640M $8.354M
Total Long-Term Liabilities $3.570M $0.00
Total Liabilities $6.707M $8.354M
YoY Change -19.71% 7.11%
SHAREHOLDERS EQUITY
Retained Earnings -$77.30M
YoY Change
Common Stock $62.14K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.385M -$5.695M
YoY Change
Total Liabilities & Shareholders Equity $8.092M $2.659M
YoY Change 204.35% -71.44%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$2.359M -$2.000M
YoY Change 17.95% -55.69%
Depreciation, Depletion And Amortization $121.9K $34.09K
YoY Change 257.73% -20.62%
Cash From Operating Activities -$1.450M -$1.483M
YoY Change -2.22% -13.98%
INVESTING ACTIVITIES
Capital Expenditures $264.1K $3.011K
YoY Change 8671.64% -101.88%
Acquisitions
YoY Change
Other Investing Activities $208.8K $1.421M
YoY Change -85.31% -393.02%
Cash From Investing Activities -$55.35K $1.418M
YoY Change -103.9% -319.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.595M 615.0K
YoY Change 159.35%
NET CHANGE
Cash From Operating Activities -1.450M -1.483M
Cash From Investing Activities -55.35K 1.418M
Cash From Financing Activities 1.595M 615.0K
Net Change In Cash 89.72K 550.3K
YoY Change -83.7% -123.23%
FREE CASH FLOW
Cash From Operating Activities -$1.450M -$1.483M
Capital Expenditures $264.1K $3.011K
Free Cash Flow -$1.714M -$1.486M
YoY Change 15.36% -4.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001477009
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NONE
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60813673
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62146515
CY2021Q1 cann Income Tax Expense Benefit Continuing And Discontinued Operations
IncomeTaxExpenseBenefitContinuingAndDiscontinuedOperations
CY2020Q1 cann Income Tax Expense Benefit Continuing And Discontinued Operations
IncomeTaxExpenseBenefitContinuingAndDiscontinuedOperations
CY2021Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
000-54457
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
GENERAL CANNABIS CORP
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
CO
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-1072649
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
6565 East Evans Avenue
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Denver
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80224
CY2021Q1 dei City Area Code
CityAreaCode
303
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
759-1300
CY2021Q1 dei Security12b Title
Security12bTitle
N/A
CY2021Q1 dei Trading Symbol
TradingSymbol
N/A
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62146515
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
840092
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
750218
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
54000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
27000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
299884
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
327790
CY2021Q1 us-gaap Allowance For Notes And Loans Receivable Current
AllowanceForNotesAndLoansReceivableCurrent
41608
CY2020Q4 us-gaap Allowance For Notes And Loans Receivable Current
AllowanceForNotesAndLoansReceivableCurrent
125000
CY2021Q1 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
260000
CY2020Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
350000
CY2021Q1 us-gaap Inventory Net
InventoryNet
419825
CY2020Q4 us-gaap Inventory Net
InventoryNet
371799
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
376910
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
744396
CY2021Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
5401
CY2020Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
5551
CY2021Q1 us-gaap Assets Current
AssetsCurrent
2202112
CY2020Q4 us-gaap Assets Current
AssetsCurrent
2549754
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1826523
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1836455
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
666306
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
455222
CY2020Q4 us-gaap Investments
Investments
208761
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
912500
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
984375
CY2021Q1 us-gaap Goodwill
Goodwill
2484200
CY2020Q4 us-gaap Goodwill
Goodwill
2484200
CY2021Q1 us-gaap Assets
Assets
8091641
CY2020Q4 us-gaap Assets
Assets
8518767
CY2021Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
733065
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1513761
CY2021Q1 us-gaap Interest Payable Current
InterestPayableCurrent
106141
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
16790
CY2021Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
75906
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
517931
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
373581
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
370800
CY2021Q1 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
60900
CY2020Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
94861
CY2021Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
236995
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
561368
CY2021Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
53128
CY2020Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
54641
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1639716
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3130152
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1497316
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1499280
CY2021Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
3276285
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
2598965
CY2021Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
293750
CY2020Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
289579
CY2021Q1 us-gaap Liabilities
Liabilities
6707067
CY2020Q4 us-gaap Liabilities
Liabilities
7517976
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62146515
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60813673
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
62144
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
60813
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
78632934
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
75891414
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77310504
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-74951436
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1384574
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1000791
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8091641
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8518767
CY2021Q1 us-gaap Revenues
Revenues
1647990
CY2020Q1 us-gaap Revenues
Revenues
1664188
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1396097
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1423980
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
750577
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1039934
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
103932
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
572574
CY2021Q1 us-gaap Professional Fees
ProfessionalFees
262914
CY2020Q1 us-gaap Professional Fees
ProfessionalFees
597036
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
121941
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
31913
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
2635461
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
3665437
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-987471
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2001249
CY2021Q1 cann Amortization Of Debt Discount And Equity Issuance Costs
AmortizationOfDebtDiscountAndEquityIssuanceCosts
68330
CY2020Q1 cann Amortization Of Debt Discount And Equity Issuance Costs
AmortizationOfDebtDiscountAndEquityIssuanceCosts
66321
CY2021Q1 us-gaap Interest Expense
InterestExpense
103056
CY2020Q1 us-gaap Interest Expense
InterestExpense
171048
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1137428
CY2021Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1198744
CY2020Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1375620
CY2021Q1 cann Other Expense Income Net
OtherExpenseIncomeNet
-1467
CY2020Q1 cann Other Expense Income Net
OtherExpenseIncomeNet
139105
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1371597
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
139928
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2359068
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1861321
CY2020Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-152858
CY2021Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-2359068
CY2020Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-2014179
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2359068
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2014179
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.04
CY2020Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.05
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61563379
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39694890
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2359068
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2014179
CY2021Q1 cann Amortization Of Debt Discount And Equity Issuance Costs
AmortizationOfDebtDiscountAndEquityIssuanceCosts
68330
CY2020Q1 cann Amortization Of Debt Discount And Equity Issuance Costs
AmortizationOfDebtDiscountAndEquityIssuanceCosts
66321
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
121941
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
34087
CY2020Q1 us-gaap Amortization Of Deferred Loan Origination Fees Net
AmortizationOfDeferredLoanOriginationFeesNet
2487
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1137428
CY2021Q1 cann Non Cash Lease Expense
NonCashLeaseExpense
103450
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-39463
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
51572
CY2021Q1 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-2964
CY2021Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1198744
CY2020Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1375620
CY2021Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
103932
CY2020Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
572574
CY2020Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-5183
CY2020Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
139105
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-157369
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-204502
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-367486
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
261778
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
48026
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1034883
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
238674
CY2021Q1 cann Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-92701
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1449925
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1482828
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
264114
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3011
CY2021Q1 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
208761
CY2020Q1 us-gaap Proceeds From Sale Of Buildings
ProceedsFromSaleOfBuildings
1421134
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55353
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1418123
CY2020Q1 cann Proceeds From Sale Of Common Stock And Warrants
ProceedsFromSaleOfCommonStockAndWarrants
90000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
135002
CY2021Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1660000
CY2020Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1500000
CY2021Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
200000
CY2020Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
975000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1595002
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
615000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
89724
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
550295
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
755769
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
224994
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
845493
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
775289
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
13705
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
173067
CY2021Q1 cann Noncash Transaction Exercise Of Warrants Amount
NoncashTransactionExerciseOfWarrantsAmount
1557078
CY2021Q1 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
417539
CY2020Q1 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
233500
CY2021Q1 cann Noncash Transaction Issuance Of Common Stock To Consultant
NoncashTransactionIssuanceOfCommonStockToConsultant
100000
CY2020Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
250000
CY2020Q1 cann Noncash Transaction Issuance Of Common Stock To Employee
NoncashTransactionIssuanceOfCommonStockToEmployee
100000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1000791
CY2021Q1 cann Stock Issued During Period Value Issued To Consultant
StockIssuedDuringPeriodValueIssuedToConsultant
100000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
135002
CY2021Q1 cann Beneficial Conversion Feature
BeneficialConversionFeature
417539
CY2021Q1 cann Cashless Warrants Exercised During Period Value
CashlessWarrantsExercisedDuringPeriodValue
1557078
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
103932
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-2359068
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1384574
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-5764212
CY2020Q1 cann Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
172241
CY2020Q1 cann Stock Options Granted To Employees
StockOptionsGrantedToEmployees
100000
CY2020Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
250000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
233500
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
492331
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-2014179
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-5694820
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1.  NATURE OF OPERATIONS, HISTORY AND PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Nature of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General Cannabis Corp, a Colorado Corporation (the “Company,” “we,” “us,” or “our,”) (formerly, Advanced Cannabis Solutions, Inc.), was incorporated on June 3, 2013, and provides services and products to the regulated cannabis industry. We currently trade on the OTCQB® Market under the trading symbol CANN. As of March 31, 2021, our operations are segregated into the following two segments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;">Operations Consulting and Products (“Operations Segment”)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Through Next Big Crop (“NBC”), we deliver comprehensive consulting services to the cannabis industry that include obtaining licenses, compliance, cultivation, retail operations, logistical support, facility design and construction, and expansion of existing operations. During the three months ended March 31, 2021 and 2020, 69% and 73% of NBC’s revenue was with three customers, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">NBC oversees our wholesale equipment and supply business, operated under the name “GC Supply,” which provides turnkey sourcing and stocking services to cultivation, retail and infused products manufacturing facilities. Our products include building materials, equipment, consumables and compliance packaging. There are generally multiple suppliers for the products we sell; however, there are a limited number of manufacturers of certain high-tech cultivation equipment. NBC also provides operational support for our internal cultivation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Cultivation (“Cultivation Segment”)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Through our acquisition of SevenFive Farm ("SevenFive") in May 2020, we operate a 17,000 square foot licensed light deprivation greenhouse cultivation facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2021, 18% of SevenFive’s revenue was with one customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying condensed consolidated financial statements include all accounts of the Company and its wholly-owned subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by accounting principles generally accepted in the United States of America ("U.S. GAAP") can be condensed or omitted. The condensed consolidated balance sheet for the year ended December 31, 2020 was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and notes thereto of the Company for the year ended December 31, 2020 which were included in the annual report on Form 10-K filed by the Company on April 1, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and notes thereto of the Company and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of the Company's financial position and operating results. The results for the three months ended March 31, 2021 are not necessarily indicative of the operating results for the year ending December 31, 2021, or any other interim or future periods. Since the date of the Annual Report, there have been no material changes to the Company’s significant accounting policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Furthermore, when testing assets for impairment in future periods, if management uses different assumptions or if different conditions occur, impairment charges may result. In particular, the COVID-19 pandemic has adversely impacted and is likely to further adversely impact the Company's business and markets. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including revenues, expenses, reserves and allowances, fair value measurements and asset impairment charges, will depend on future developments that are highly uncertain and difficult to predict. These developments include, but are not limited to, the duration and spread of the pandemic, its severity in our markets and elsewhere, governmental actions to contain the spread of the pandemic and respond to the reduction in global economic activity, and how quickly and to what extent normal economic and operating conditions can resume.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Discontinued Operations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On December 26, 2019, the board of directors and management made the strategic decision to discontinue the operations for both the Security Segment and the Consumer Goods Segment. The assets and liabilities classified as discontinued operations for the Security Segment and Consumer Goods Segment are presented separately in the balance sheet and the operating results. The cash flows related to discontinued operations have not been segregated and are included in the consolidated statements of cash flows. As of March 31, 2021, and December 31, 2020, there are $5,401 and $5,551 of cash and cash equivalents included in asset of discontinued operations on the balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">On January 1, 2021 we discontinued our investments segment. As this is not a materially significant segment, we have not shown the effects of the discontinued segment in the financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="text-decoration:underline;">Going Concern</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company incurred net losses of $2.4 million and $2.0 million in three months ended March 31, 2021 and 2020, respectively, and had an accumulated deficit of $77.3 million as of March 31, 2021. The Company had cash, cash equivalents, and short-term and long-term investments of $0.8 million and $1.0 million as of March 31, 2021 and December 31, 2020, respectively.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses and negative cash flows from operations since inception and has primarily funded its operations with proceeds from the issuance of convertible debt. The Company expects its operating losses to continue into the foreseeable future as it continues to execute its acquisition and growth strategy.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company believes that its cash, cash equivalents, and short-term investments as of March 31, 2021 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of filing this Quarterly Report on Form 10-Q due to the receipt of an additional $2.3 million of cash in April 2021 from the issuance of a convertible note offering and the pending acquisition of three dispensaries (See Note 13 for further information). The Company may need additional funding to support its planned investing activities. If the Company is unable to obtain additional funding, it would be forced to delay, reduce or eliminate some or all of its acquisition efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">See our Annual Report on Form 10-K for the year ended December 31, 2020, for discussion of the Company's significant accounting policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">FASB ASU 2020-06 – “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”- </i><span style="white-space:pre-wrap;">In June 2020, the Financial Accounting Standards Board (“FASB”) issued guidance which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Accounting Standards Updates (“ASU”) also removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share calculation in certain areas. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2021, although early adoption is permitted. We are in the process of evaluating the impact of this new guidance on our consolidated financial statements.</span><i style="font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">FASB ASU 2019-12 – “Income Taxes (Topic 740)”</i> –<i style="font-style:italic;"> </i>In December 2019, the FASB issued guidance which simplifies certain aspects of accounting for income taxes. The guidance is effective for interim and annual reporting periods beginning after December 15, 2020, and early adoption is permitted. We adopted this ASU in the first quarter of 2021. This ASU did not have a material effect on our condensed consolidated financial statements.</p>
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2021Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</p>
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Furthermore, when testing assets for impairment in future periods, if management uses different assumptions or if different conditions occur, impairment charges may result. In particular, the COVID-19 pandemic has adversely impacted and is likely to further adversely impact the Company's business and markets. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including revenues, expenses, reserves and allowances, fair value measurements and asset impairment charges, will depend on future developments that are highly uncertain and difficult to predict. These developments include, but are not limited to, the duration and spread of the pandemic, its severity in our markets and elsewhere, governmental actions to contain the spread of the pandemic and respond to the reduction in global economic activity, and how quickly and to what extent normal economic and operating conditions can resume.</p>
CY2021Q1 cann Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.04
CY2021Q1 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
5401
CY2020Q4 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
5551
CY2020Q1 cann Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.04
CY2021Q1 cann Business Acquisition Pro Forma Weighted Average Number Of Shares Outstanding Basic And Diluted
BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted
61563379
CY2020Q1 cann Business Acquisition Pro Forma Weighted Average Number Of Shares Outstanding Basic And Diluted
BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted
48554007
CY2021Q1 cann Going Concern
GoingConcern
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="text-decoration:underline;">Going Concern</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company incurred net losses of $2.4 million and $2.0 million in three months ended March 31, 2021 and 2020, respectively, and had an accumulated deficit of $77.3 million as of March 31, 2021. The Company had cash, cash equivalents, and short-term and long-term investments of $0.8 million and $1.0 million as of March 31, 2021 and December 31, 2020, respectively.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses and negative cash flows from operations since inception and has primarily funded its operations with proceeds from the issuance of convertible debt. The Company expects its operating losses to continue into the foreseeable future as it continues to execute its acquisition and growth strategy.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company believes that its cash, cash equivalents, and short-term investments as of March 31, 2021 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of filing this Quarterly Report on Form 10-Q due to the receipt of an additional $2.3 million of cash in April 2021 from the issuance of a convertible note offering and the pending acquisition of three dispensaries (See Note 13 for further information). The Company may need additional funding to support its planned investing activities. If the Company is unable to obtain additional funding, it would be forced to delay, reduce or eliminate some or all of its acquisition efforts, which could adversely affect its business prospects.</p>
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2400000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2000000.0
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77300000
CY2021Q1 cann Cash Cash Equivalents And Investments
CashCashEquivalentsAndInvestments
800000
CY2020Q1 cann Cash Cash Equivalents And Investments
CashCashEquivalentsAndInvestments
1000000.0
CY2021Q2 cann Proceeds From Issuance Of Convertible Notes Offering
ProceedsFromIssuanceOfConvertibleNotesOffering
2300000
CY2021Q1 cann Number Of Dispensaries
NumberOfDispensaries
3
CY2021Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
1647990
CY2020Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
2312231
CY2021Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-2359068
CY2020Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-1814318
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
517931
CY2021Q1 cann Deferred Revenue Additional Deposits Received During Period Current
DeferredRevenueAdditionalDepositsReceivedDuringPeriodCurrent
321772
CY2021Q1 cann Deferred Revenue Deposits Recognized As Revenue During Period Current
DeferredRevenueDepositsRecognizedAsRevenueDuringPeriodCurrent
763797
CY2021Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
75906
CY2021Q1 us-gaap Inventory Finished Goods And Work In Process
InventoryFinishedGoodsAndWorkInProcess
419825
CY2020Q4 us-gaap Inventory Finished Goods And Work In Process
InventoryFinishedGoodsAndWorkInProcess
371799
CY2021Q1 us-gaap Inventory Net
InventoryNet
419825
CY2020Q4 us-gaap Inventory Net
InventoryNet
371799
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
278100
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
381924
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
387653
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
393468
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
399370
CY2021Q1 cann Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
4048779
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5889294
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4018397
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1870897
CY2020 cann Increase In Accrued Common Stock Payable Warrant Cashless Exercises Shares
IncreaseInAccruedCommonStockPayableWarrantCashlessExercisesShares
259415
CY2021Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1029965
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
251456
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
3570035
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
2888544
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3570035
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2888544
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.00
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
561368
CY2019Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
4620593
CY2021Q1 cann Fair Value Of Warrants Exercised
FairValueOfWarrantsExercised
-1539981
CY2020Q1 cann Fair Value Of Warrants Exercised
FairValueOfWarrantsExercised
-82241
CY2021Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
1198744
CY2020Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-1375619
CY2021Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
220131
CY2020Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
3162733
CY2020Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
572574
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
895500
CY2021Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
103932
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P5Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P1Y
CY2021Q1 cann Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
561237
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7266420
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.03
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
167000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
895500
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.94
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
213860
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.63
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
31000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.95
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7917060
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.02
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y3M18D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1614000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
5340940
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
1.20
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
868000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
803599
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P13M
CY2020Q4 cann Number Of Board Members
NumberOfBoardMembers
5
CY2021Q1 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
9500
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2021Q1 us-gaap Assets Net
AssetsNet
8091641
CY2020Q4 us-gaap Assets Net
AssetsNet
8513217

Files In Submission

Name View Source Status
0001558370-21-007388-index-headers.html Edgar Link pending
0001558370-21-007388-index.html Edgar Link pending
0001558370-21-007388.txt Edgar Link pending
0001558370-21-007388-xbrl.zip Edgar Link pending
cann-20210331.xsd Edgar Link pending
cann-20210331x10q.htm Edgar Link pending
cann-20210331x10q_htm.xml Edgar Link completed
cann-20210331xex31d1.htm Edgar Link pending
cann-20210331xex31d2.htm Edgar Link pending
cann-20210331xex32d1.htm Edgar Link pending
cann-20210331_cal.xml Edgar Link unprocessable
cann-20210331_def.xml Edgar Link unprocessable
cann-20210331_lab.xml Edgar Link unprocessable
cann-20210331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending